Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $169.16M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.16M
Average 0.16M
ORMP Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Oramed Pharmaceuticals Inc.NASDAQ: ORMP
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $1.59M fell 27.7% year over year, behind the -21.5% change in trailing-twelve-month research & development. Sequentially, it fell 19.8% from the prior quarter. Over 3 fiscal years it compounded at -38.7% a year.
Context
- Research & development amounted to 319.1% of revenue in FY2025.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -27.7% toward the trailing-twelve-month pace of -21.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 6.38M USD
- Year-over-year change
- +0.9%
- 4-year CAGR
- -25.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.38M | +0.9% |
| FY2024 | 2024-12-31 | 6.32M | -29.5% |
| FY2023 | 2023-12-31 | 8.97M | -67.5% |
| FY2022 | 2022-12-31 | 27.64M | +31.7% |
| FY2021 | 2021-08-31 | 20.99M | — |
Research & Development vs competitors
How ORMP compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -21.5% is the 8th highest of 11, against a peer median of -13.4%.
- Over three fiscal years its annual growth of -38.7% compares with a peer median of -12.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.68B USD | +26273.1% | +50.2% | 46313.4% | |
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| FY2025 | $37.8M USD | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $36.3M USD | -40.4% | -24.8% | 3629.9% | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $32.3M USD | -29.1% | +37.8% | — |
IMAImageneBio Inc | LTM Mar 2026 | $30.77M USD | +23.4% | -23.7% | — |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | €22.87M EUR | -34.8% | -11.8% | 77989.1% | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| LTM Mar 2026 | $5.77M USD | -21.5% | -38.7% | — | |
| Peer median (excluding ORMP) | — | -13.4% | -12.0% | 9596.3% | |
Competitors are the stored peer set for ORMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.7M | 2.7M | 1.34M | 0 | 2M |
| Cost of Revenue | 0 | 0 | 0 | 193K | 1.99M |
| Gross Profit | 2.7M | 2.7M | 1.34M | (193K) | 13K |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 0.7% |
| Research & Development | 20.99M | 27.64M | 8.97M | 6.32M | 6.38M |
| Selling, General & Admin | 5.94M | 15.66M | 8.14M | 6.46M | 8.72M |
| Operating Expenses | 26.93M | 43.3M | 17.11M | 12.78M | 15.1M |
| Depreciation & Amortization | 77K | 3.62M | 196K | 193K | 121K |
| EBITDA | (25.04M) | (36.98M) | 7.32M | (14.87M) | 75.45M |
| EBITDA Margin | -926.3% | -1368.0% | 546.3% | — | 3772.2% |
| Operating Income | (24.22M) | (40.6M) | (15.77M) | (12.78M) | (15.09M) |
| Operating Margin | -896.2% | -1502.0% | -1176.8% | — | -754.4% |
| Interest Income | 347K | 3.57M | 8.03M | 0 | 2.37M |
| Interest Expense | 6K | 0 | 3.58M | 853K | 0 |
| Other Income / Expenses | 893K | 2.93M | 20.86M | (3.14M) | 90.41M |
| Income Before Tax | (22.99M) | (37.66M) | 5.09M | (15.92M) | 75.32M |
| Pre-Tax Margin | -850.5% | -1393.4% | 379.7% | — | 3766.2% |
| Income Tax Expense | (2.88M) | 100K | 0 | 3.18M | 11.31M |
| Net Income | (22.24M) | (37.76M) | 5.53M | (19.1M) | 64.05M |
| Net Margin | -822.7% | -1397.1% | 412.3% | — | 3202.5% |
| EPS (Basic) | (0.78) | (0.97) | 0.14 | (0.47) | 1.53 |
| EPS (Diluted) | (0.78) | (0.97) | 0.14 | (0.47) | 1.50 |
| Weighted Avg Shares | 28.47M | 39M | 40.32M | 40.83M | 41.4M |
| Weighted Avg Shares (Diluted) | 28.47M | 39M | 40.57M | 40.83M | 42.42M |
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
Intrinsic Alpha fair value
Locked
Current Price
$3.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.